Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7P51

CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE COMPLEXED WITH FRAGMENT F01

Summary for 7P51
Entry DOI10.2210/pdb7p51/pdb
Related7NTS 7NTT
Descriptor3C-like proteinase, SODIUM ION, DIMETHYL SULFOXIDE, ... (5 entities in total)
Functional Keywords3clpro, main protease, sars-cov-2, 2019-ncov, inhibitor, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2)
Total number of polymer chains1
Total formula weight34346.51
Authors
Hanoulle, X.,Moschidi, D. (deposition date: 2021-07-13, release date: 2021-10-06, Last modification date: 2024-01-31)
Primary citationCantrelle, F.X.,Boll, E.,Brier, L.,Moschidi, D.,Belouzard, S.,Landry, V.,Leroux, F.,Dewitte, F.,Landrieu, I.,Dubuisson, J.,Deprez, B.,Charton, J.,Hanoulle, X.
NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment.
Angew.Chem.Int.Ed.Engl., 60:25428-25435, 2021
Cited by
PubMed Abstract: The main protease (3CLp) of the SARS-CoV-2, the causative agent for the COVID-19 pandemic, is one of the main targets for drug development. To be active, 3CLp relies on a complex interplay between dimerization, active site flexibility, and allosteric regulation. The deciphering of these mechanisms is a crucial step to enable the search for inhibitors. In this context, using NMR spectroscopy, we studied the conformation of dimeric 3CLp from the SARS-CoV-2 and monitored ligand binding, based on NMR signal assignments. We performed a fragment-based screening that led to the identification of 38 fragment hits. Their binding sites showed three hotspots on 3CLp, two in the substrate binding pocket and one at the dimer interface. F01 is a non-covalent inhibitor of the 3CLp and has antiviral activity in SARS-CoV-2 infected cells. This study sheds light on the complex structure-function relationships of 3CLp and constitutes a strong basis to assist in developing potent 3CLp inhibitors.
PubMed: 34570415
DOI: 10.1002/anie.202109965
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.474 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon